Khalid Salaheldin, MD
Clinical Assistant Professor, Psychiatry and Behavioral Sciences
Bio
Khalid Salaheldin, MD, holds the position of Clinical Assistant Professor and serves as an interventional psychiatrist within the Department of Psychiatry & Behavioral Sciences at Stanford University School of Medicine. His expertise lies in the specialized care of individuals who present with early psychosis.
At Stanford, Dr. Salaheldin's current responsibilities encompass a range of clinical activities, including evaluating patients with early psychosis at the INSPIRE clinic, providing care in the inpatient psychiatric unit, and delivering interventional psychiatry services. In addition to his clinical work, he is actively engaged in teaching, conducting research, and fostering collaborative learning among his patients and colleagues.
His treatment philosophy is a recovery oriented and compassionate approach evaluating vital underlying factors alongside pharmacotherapy & neuromodulatory interventions including: sleep, exercise, nutrition, mindfulness, therapy integration, underlying medical issues, substance use, psychosocial history, and importantly patients’ current relationships (including pets of course!). His approach focuses on meeting patients where they are at in their health journey, aligning treatment with their personal goals, and being actively present in their management.
Dr. Salaheldin’s research interests include early psychosis interventions, underlying medical causes of psychiatric symptoms, neuromodulation, community/global mental health, spirituality and mental health, healthcare worker mental health, novel psychiatric therapeutics, and mental health parity & policy.
Before joining Stanford, Dr. Salaheldin served as the academic chief resident at Northwell Health, where his focus centered on designing a consult liaison service for patients experiencing a first episode of psychosis. This pioneering initiative aimed to provide compassionate support to patients and their families from the moment they arrived at the emergency room, throughout their inpatient stay, and during their transition to the outpatient setting. He hopes to continue this work on a local and global scale.
“True compassion means not only feeling another's pain, but also being moved to help relieve it. ” —Daniel Goleman
Clinical Focus
- Psychiatry
- Early Psychosis Interventions
- Schizophrenia
- Interventional Psychiatry
- Nutritional Psychiatry
- Novel Therapeutics
- Preventative Psychiatry/Medicine
Academic Appointments
-
Clinical Assistant Professor, Psychiatry and Behavioral Sciences
Administrative Appointments
-
Assistant Medical Director, INSPIRE Clinic (2022 - Present)
Honors & Awards
-
Excellence in Teaching Award, Stanford School of Medicine, Psychiatry & Behavioral Sciences (2023)
-
Academic Chief Resident, Northwell Health (2020-2021)
-
Biology Scholars Program, UC Berkeley (2008-2009)
Boards, Advisory Committees, Professional Organizations
-
Consultant, Muslim Mental Health Lab (2022 - Present)
-
Affiliated Faculty, Wu Tsai Neurosciences Institute (2023 - Present)
Professional Education
-
Board Certification: American Board of Psychiatry and Neurology, Psychiatry
-
Medical Education: St George's University School of Medicine Grenada West Indies (2017) NY West Indies
-
ABPN Dipolmate, Board Certification, American Board of Psychiatry and Neurology, Psychiatry (2021)
-
Residency: Zucker School of Medicine at Hofstra Northwell GME Program (2021) NY
-
BA, University of California Berkeley, Public Health (2009)
-
BA, University of California Santa Cruz (Transfer to UC Berkeley) (2007)
-
HSDG, Lowell High School, San Francisco, CA (2005)
Community and International Work
-
EPICAL State Taskforce for Early Psychosis Intervention
Topic
Early Psychosis Intervnention
Partnering Organization(s)
Stanford, UC Davis, UCSF, UC San Diego
Location
International
Ongoing Project
Yes
Opportunities for Student Involvement
No
Clinical Trials
-
A Study to Assess Efficacy and Safety of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia
Recruiting
This is a Phase 3, 6-week, randomized, double-blind, placebo-controlled, multicenter, outpatient study in subjects with schizophrenia with an inadequate response to their current atypical antipsychotic treatment. The primary objective of the study is to assess the efficacy of adjunctive KarXT (a fixed dose combination of xanomeline and trospium chloride twice daily \[BID\]) versus placebo in the treatment of subjects with inadequately controlled symptoms of schizophrenia as measured by the Positive and Negative Syndrome Scale (PANSS) Total Score.
-
An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia
Recruiting
This is a Phase 3, multicenter, 52-week, outpatient, open-label extension (OLE) study to evaluate the long-term safety and tolerability of adjunctive KarXT in subjects with schizophrenia with an inadequate response to their current antipsychotic treatment who previously completed the treatment period (Visit 8/Day 42 ± 3) of ARISE Study (KAR-012). The primary objective of the study is to assess the long-term safety and tolerability of adjunctive KarXT (a fixed dose combination of xanomeline and trospium chloride twice daily \[BID\]) in subjects with schizophrenia.
-
A Study to Assess the Effects of RO6889450 (Ralmitaront) in Participants With Schizophrenia or Schizoaffective Disorder and Negative Symptoms
Not Recruiting
This study investigates the effects of RO6889450 on the negative symptoms associated with schizophrenia and schizoaffective disorder.
Stanford is currently not accepting patients for this trial.
-
CONNEX-3: A Study to Test Whether Iclepertin Improves Learning and Memory in People With Schizophrenia
Not Recruiting
This study is open to adults with schizophrenia. Schizophrenia can affect the way a person thinks, their memory and their mental functioning. Examples include struggling to remember things, or to read a book or pay attention to a movie. Some people have difficulty calculating the right change or planning a trip so that they arrive on time. The purpose of this study is to find out whether a medicine called iclepertin improves learning and memory in people with schizophrenia. Participants are put into two groups randomly, which means by chance. One group takes iclepertin tablets and the other group takes placebo tablets. Placebo tablets look like iclepertin tablets but do not contain any medicine. Participants take a tablet once a day for 26 weeks. In addition, all participants take their normal medication for schizophrenia. During this time, doctors regularly test learning and memory of the participants by use of questionnaires, interviews, and computer tests. The results of the mental ability tests are compared between the groups. Participants are in the study for about 8 months and visit the study site about 14 times. During this time, doctors regularly check participants' health and take note of any unwanted effects.
Stanford is currently not accepting patients for this trial. For more information, please contact Daniel Virtheim, (650) 353-7030.
-
Improving Cognition Via Exercise in Schizophrenia
Not Recruiting
People with schizophrenia display a broad range of cognitive impairments that have been identified as major determinants of poor functioning and disability. Also, people with schizophrenia are at increased risk for suicide, with approximately 40-50% of individuals attempting to take their own lives during their lifetime. The goal of the proposed study is to examine the impact of remote exercise training on cognition, suicide risk, daily functioning, and biomarkers of cognitive change and suicidality in people with schizophrenia.
Stanford is currently not accepting patients for this trial. For more information, please contact Daniel Virtheim, 650-353-7030.
-
Journey Study: Evaluate the Efficacy, Safety, and Tolerability of Valbenazine As Adjunctive Treatment for Schizophrenia
Not Recruiting
The primary objective for this study is to evaluate the effect of adjunctive valbenazine versus placebo on symptoms of schizophrenia in participants who have inadequate response to antipsychotic treatment.
Stanford is currently not accepting patients for this trial. For more information, please contact Diane Wakeham, (650) 736- 5243.
-
Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831
Not Recruiting
This study will evaluate the long-term safety, tolerability, and durability of treatment effect of ALKS 3831 in subjects with schizophrenia, schizophreniform disorder, or bipolar I disorder
Stanford is currently not accepting patients for this trial.
Projects
-
The Genomics of Electroconvulsive Therapy (ECT)
IRB-54241
Location
stanford, ca
All Publications
-
I THINK MY PATIENT MAY BE EXPERIENCING PSYCHOSIS - NOW WHAT? HOW PROVIDERS CAN SUPPORT EARLY IDENTIFICATION AND INTERVENTION.
OXFORD UNIV PRESS INC. 2022: S1
View details for Web of Science ID 000788118600003
-
The relationship between prototype ratings of personality and self and interpersonal functioning with an adolescent inpatient sample
CLINICAL PSYCHOLOGY & PSYCHOTHERAPY
2021; 28 (2): 364-372
Abstract
Personality pathology is conceptualized, in part, as impairments in self and interpersonal functioning. Although most of the research has focused on adult samples, fewer have looked at this relationship in adolescent samples. This paper investigates the relationship between clinician-rated personality prototypes, the Shedler-Westen Assessment Procedure-Prototype Matching Adolescent Version (SWAP-A-P) derived from the SWAP-II-A, and a measure of self and interpersonal functioning, the Social Cognition and Object Relation Scale-Global Rating (SCORS-G). Clinicians rated 66 adolescents hospitalized at a safety net teaching hospital in the northeast. The patient's individual and group therapist rated the patients at discharge using the SWAP-A-P and the SCORS-G at discharge blind to each other's ratings. Results showed that more severe personality pathology was linked with more impairments in self and interpersonal functioning.
View details for DOI 10.1002/cpp.2512
View details for Web of Science ID 000585999700001
View details for PubMedID 32881158
- Phobias 5MinuteConsult Wolters Kluwer. 2020